JP2022176154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022176154A5 JP2022176154A5 JP2022078503A JP2022078503A JP2022176154A5 JP 2022176154 A5 JP2022176154 A5 JP 2022176154A5 JP 2022078503 A JP2022078503 A JP 2022078503A JP 2022078503 A JP2022078503 A JP 2022078503A JP 2022176154 A5 JP2022176154 A5 JP 2022176154A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- pharmaceutical composition
- composition according
- polysorbate
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 108020001507 fusion proteins Proteins 0.000 claims 17
- 102000037865 fusion proteins Human genes 0.000 claims 17
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 15
- 229920001983 poloxamer Polymers 0.000 claims 15
- 229960000502 poloxamer Drugs 0.000 claims 15
- 229920000136 polysorbate Polymers 0.000 claims 15
- 229950008882 polysorbate Drugs 0.000 claims 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 10
- -1 polyoxyethylene Polymers 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000002016 disaccharides Chemical class 0.000 claims 9
- 230000007935 neutral effect Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000872 buffer Substances 0.000 claims 8
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 6
- 102000007238 Transferrin Receptors Human genes 0.000 claims 6
- 108010033576 Transferrin Receptors Proteins 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 5
- 229920001451 polypropylene glycol Polymers 0.000 claims 5
- 229920000053 polysorbate 80 Polymers 0.000 claims 5
- 229940068968 polysorbate 80 Drugs 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 3
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 claims 3
- 238000002641 enzyme replacement therapy Methods 0.000 claims 3
- 102000056929 human IDUA Human genes 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080729 | 2021-05-12 | ||
| JP2021080729 | 2021-05-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022176154A JP2022176154A (ja) | 2022-11-25 |
| JP2022176154A5 true JP2022176154A5 (enExample) | 2025-05-19 |
Family
ID=84029664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078503A Pending JP2022176154A (ja) | 2021-05-12 | 2022-05-11 | ムコ多糖症ｉ型の治療用医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240269244A1 (enExample) |
| EP (1) | EP4335459A4 (enExample) |
| JP (1) | JP2022176154A (enExample) |
| KR (1) | KR20240007163A (enExample) |
| CN (1) | CN117279665A (enExample) |
| TW (1) | TW202306992A (enExample) |
| WO (1) | WO2022239817A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023011087A (es) * | 2021-03-24 | 2023-10-02 | Japan Chem Res | Composicion farmaceutica acuosa o composicion farmaceutica liofilizada estable. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
| JP6279466B2 (ja) | 2012-04-27 | 2018-02-14 | Ｊｃｒファーマ株式会社 | 新規な発現ベクター |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| EP3561058B1 (en) * | 2016-12-26 | 2025-07-23 | JCR Pharmaceuticals Co., Ltd. | Fusion protein including bdnf |
| JP6956741B2 (ja) | 2016-12-26 | 2021-11-02 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
| KR102471458B1 (ko) * | 2016-12-28 | 2022-11-25 | 제이씨알 파마 가부시키가이샤 | 동결건조 제제 |
| US11932699B2 (en) * | 2017-09-07 | 2024-03-19 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition |
| US20240158436A1 (en) * | 2021-03-09 | 2024-05-16 | Jcr Pharmaceuticals Co., Ltd. | Method for Producing Antibody-Lysosomal Enzyme Fusion Protein |
| MX2023011087A (es) * | 2021-03-24 | 2023-10-02 | Japan Chem Res | Composicion farmaceutica acuosa o composicion farmaceutica liofilizada estable. |
-
2022
- 2022-05-11 WO PCT/JP2022/020001 patent/WO2022239817A1/ja not_active Ceased
- 2022-05-11 CN CN202280033472.XA patent/CN117279665A/zh active Pending
- 2022-05-11 EP EP22807516.4A patent/EP4335459A4/en active Pending
- 2022-05-11 KR KR1020237038968A patent/KR20240007163A/ko active Pending
- 2022-05-11 JP JP2022078503A patent/JP2022176154A/ja active Pending
- 2022-05-11 US US18/290,001 patent/US20240269244A1/en active Pending
- 2022-05-12 TW TW111117776A patent/TW202306992A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW520291B (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| EP3967755B1 (en) | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum | |
| EP2726090B1 (en) | Arginine - free tnfr : fc- fusion polypeptide compositions | |
| JP2004502456A5 (enExample) | ||
| JP2002544174A5 (enExample) | ||
| GB2112641A (en) | The use of peptides as medicaments | |
| EP0939648B1 (en) | Rotavirus vaccine formulations | |
| JP2022176154A5 (enExample) | ||
| TW202306992A (zh) | 第i型黏多醣症之治療用醫藥組成物 | |
| KR20250048156A (ko) | 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료 | |
| JPWO2020264333A5 (enExample) | ||
| US12064466B2 (en) | Methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases | |
| Roberton et al. | Failure of intraventricular gammaglobulin and alpha interferon for persistent encephalitis in congenital hypogammaglobulinaemia. | |
| Stratigos et al. | Treatment of gonorrhoea with spectinomycin hydrochloride | |
| HK40116513A (en) | Methods of treating tissue calcification | |
| CN120936377A (zh) | 一种稳定的抗vegf抗体制剂 | |
| HK40070846B (en) | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| CN121194795A (zh) | 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞 | |
| JP2025527521A (ja) | 急性呼吸不全の治療 | |
| HK40070846A (en) | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum | |
| AU2008202660B2 (en) | Rotavirus vaccine formulations | |
| WO2013022058A1 (ja) | ビリルビン排泄促進剤 | |
| CN119907677A (zh) | 在治疗黄斑水肿或视网膜静脉阻塞中使用的单体膜联蛋白a5 | |
| CN119139449A (zh) | 一种多肽在调节血糖中的应用 |